ANALYSIS REPORT

Patient Number Birthdate Sex Page

QUEST CAPARRA REFERENCE
Col. Tec. Med. P.R. 9/26/1968 M 1
CAPARRA GALLERY
Pat. No.: 0000197
107 ORTEGON SUITE 103 Paid 5 Cents Physician Name
GUAYNABO, PR 00966-2516 Exp: 2/28/2021
DIRECTOR: MANUEL MARCIAL-SEOANE MD
Num: 001479378 BATISTA-DELFAUS, GUARIONEX
LIC # 060 CLIA # 40D2037283 TEL: (787) 474-2900 FAX: (787) 474-5783 Origin / Special Instructions
016444975 0900-010124-000-0000 010124-DEPT SALUD-FR MUN COAMO

Request 1001479378 Reference Ordered On Supervisor

COLON-RIVERA, LUIS AUG 28,2020 11:54PM MMS
HACIENDA DEL RIO CALLED F 33
COAMO, PR 00769 FIRST RESPONDE Reported On M.T.
TEC LABORATORIO SEP 1,2020 12:21AM AHA

Test Units Results Graphic Normal Range

Molecular Diagnostics

SARS-CoV-2 RNA, PCR......................Negative Negative

****************************************************************************
For Negative Results: The specimen is negative for SARS-CoV-2, the
coronavirus associated with COVID-19. A negative result does not rule out
the possibility of COVID-19 and should not be used as the sole basis for
patient management decisions.
For Positive Results: The specimen is positive for SARS-CoV-2, the
coronavirus associated with COVID-19. Clinical correlation with patient
history and other diagnostics information is necessary to determine patient
infection status.
----------------------------------------------------------------------------
Due to the current public health emergency, Quest Diagnostics is receiving a
high volume of samples from a wide variety of swabs and media for COVID-19
testing. In order to serve patients during this public health crisis,
samples from appropriate clinical sources are being tested. Negative test
results derived from specimens received in non-commercially manufactured
viral collection and transport media, or in media and sample collection kits
not yet authorized by FDA for COVID-19 testing should be cautiously
evaluated and the patient potentially subjected to extra precautions such as
additional clinical monitoring, including collection of an additional
specimen.
This test has been authorized by FDA under an Emergency Use Authorization
(EUA) for use by authorized laboratories.
Please review the “Fact Sheets” for health care providers, and patients and
the FDA authorized labeling available on the Quest website:
www.QuestDiagnostics.com/Covid19
Method: ABBOTT m2000 Real Time SARS-CoV-2 Assay.

ORIGINAL